HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Bruno J. Messmer Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seghaye, M.-C. Articles by von Bernuth, G. Search for Related Content PubMed PubMed Citation Articles by Seghaye, M.-C. Articles by von Bernuth, G.

Ann Thorac Surg 1996;61:1205-1211
© 1996 The Society of Thoracic Surgeons

---

Original Article: Cardiovascular

Influence of Low-Dose Aprotinin on the Inflammatory Reaction Due to Cardiopulmonary Bypass in Children

Departments of Pediatric Cardiology and Thoracic and Cardiovascular Surgery, Aachen University of Technology, Aachen, Germany, and Department of Immunology, University Hospitals Brugmann and St. Pierre, Free University, Brussels, Belgium

Accepted for publication December 18, 1995.

Background. The serine protease inhibitor aprotinin inhibits trypsin, kallikrein, and plasmin and enhances the complement hemolytic activity of the first complement component C1. We tested whether low-dose aprotinin influences the inflammatory reaction related to cardiopulmonary bypass.

Methods. In an open, randomized study, 25 children undergoing cardiac operations were investigated prospectively. The treated group comprised 11 patients receiving low-dose aprotinin (20,000 kIU/kg [2.8 mg/kg]), and the control group included 14 patients. Complement activation, cytokine production, and leukocyte stimulation were analyzed before, during, and after cardiopulmonary bypass.

Results. In all children, significant C3 conversion and C5a generation, interleukin-6 synthesis, and myeloperoxidase, eosinophil cationic protein, and histamine liberation occurred in relation to cardiopulmonary bypass. This was not influenced by aprotinin treatment. In contrast, neutrophil kinetic studies at the end of cardiopulmonary bypass showed a significantly lower increase in the aprotinin as compared with the control group.

Conclusions. Our results suggest that low-dose aprotinin has little influence on the inflammatory reaction induced by cardiopulmonary bypass. Aprotinin affects neutrophil mobilization but not white blood cell degranulation related to cardiopulmonary bypass, and has no influence on complement activation and interleukin-6 synthesis.

This article has been cited by other articles:

				M. P. Eaton Antifibrinolytic Therapy in Surgery for Congenital Heart Disease Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100. [Abstract] [Full Text] [PDF]

				C. W. Hogue and M. J. London Aprotinin Use During Cardiac Surgery: A New or Continuing Controversy? Anesth. Analg., November 1, 2006; 103(5): 1067 - 1070. [Full Text] [PDF]

				D. M. Arnold, D. A. Fergusson, A. K.C. Chan, R. J. Cook, G. A. Fraser, W. Lim, M. A. Blajchman, and D. J. Cook Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin. Anesth. Analg., March 1, 2006; 102(3): 731 - 737. [Abstract] [Full Text] [PDF]

				G. J. Vlahakes The Value of Phase 4 Clinical Testing N. Engl. J. Med., January 26, 2006; 354(4): 413 - 415. [Full Text] [PDF]

				S. Mirsadraee, A. Fraser, M. A Kerr, T. E James, and C. van Doorn Inflammatory response in an immunosuppressed patient with Wegener's granulomatosis Perfusion, March 1, 2004; 19(2): 127 - 131. [Abstract] [PDF]

				Y. Hayashi, Y. Sawa, N. Fukuyama, Y. Miyamoto, T. Takahashi, H. Nakazawa, and H. Matsuda Leukocyte-depleted terminal blood cardioplegia provides superior myocardial protective effects in association with myocardium-derived nitric oxide and peroxynitrite production for patients undergoing prolonged aortic crossclamping for more than 120 minutes J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1813 - 1821. [Abstract] [Full Text] [PDF]

				H. Mossinger, W. Dietrich, S. L. Braun, M. Jochum, H. Meisner, and J. A. Richter High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery Ann. Thorac. Surg., February 1, 2003; 75(2): 430 - 437. [Abstract] [Full Text] [PDF]

				R. J. Frumento, C. M.N. O'Malley, and E. Bennett-Guerrero Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens Ann. Thorac. Surg., February 1, 2003; 75(2): 479 - 483. [Abstract] [Full Text] [PDF]

				H. H. Hovels-Gurich, J. F. Vazquez-Jimenez, A. Silvestri, K. Schumacher, R. Minkenberg, J. Duchateau, B. J. Messmer, G. von Bernuth, and M.-C. Seghaye Production of proinflammatory cytokines and myocardial dysfunction after arterial switch operation in neonates with transposition of the great arteries J. Thorac. Cardiovasc. Surg., October 1, 2002; 124(4): 811 - 820. [Abstract] [Full Text] [PDF]

				L. Englberger, B. Kipfer, P. A. Berdat, U. E. Nydegger, and T. P. Carrel Aprotinin in coronary operation with cardiopulmonary bypass: does "low-dose" aprotinin inhibit the inflammatory response? Ann. Thorac. Surg., June 1, 2002; 73(6): 1897 - 1904. [Abstract] [Full Text] [PDF]

				H. A. Hennein Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255. [Abstract] [PDF]

				Y. Hayashi, Y. Sawa, S. Ohtake, N. Fukuyama, H. Nakazawa, and H. Matsuda Peroxynitrite formation from human myocardium after ischemia-reperfusion during open heart operation Ann. Thorac. Surg., August 1, 2001; 72(2): 571 - 576. [Abstract] [Full Text] [PDF]

				L. A. Gramlich and S. D. Barnes Aprotinin Use in Pediatric Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2001; 5(1): 117 - 121. [Abstract] [PDF]

				N. Hayashida, H. Tomoeda, T. Oda, E. Tayama, S. Chihara, T. Kawara, and S. Aoyagi Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass Ann. Thorac. Surg., November 1, 1999; 68(5): 1661 - 1667. [Abstract] [Full Text] [PDF]

				P. Pouard Review of Efficacy Parameters Ann. Thorac. Surg., June 1, 1998; 65(90060): S40 - 44. [Abstract] [Full Text] [PDF]

				H. Mossinger and W. Dietrich Activation of Hemostasis During Cardiopulmonary Bypass and Pediatric Aprotinin Dosage Ann. Thorac. Surg., June 1, 1998; 65(90060): S45 - 51. [Abstract] [Full Text] [PDF]

				J. Boldt Endothelial-Related Coagulation in Pediatric Surgery Ann. Thorac. Surg., June 1, 1998; 65(90060): S56 - 59. [Abstract] [Full Text] [PDF]

				K. Al Ebrahim, M. Tahir, and H. Shafei First Open-Heart Surgery in Alport Syndrome Asian Cardiovasc Thorac Ann, March 1, 1998; 6(1): 71 - 72. [Abstract] [Full Text] [PDF]

				S. Ashraf, Y. Tian, D. Cowan, U. Nair, R. Chatrath, N. R. Saunders, K. G. Watterson, and P. G. Martin ""Low-Dose"" Aprotinin Modifies Hemostasis but Not Proinflammatory Cytokine Release Ann. Thorac. Surg., January 1, 1997; 63(1): 68 - 73. [Abstract] [Full Text]